{"id":36110,"date":"2021-06-07T16:11:00","date_gmt":"2021-06-07T14:11:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/exelixis-and-ipsen-announce-detailed-results-from-phase-3-cosmic-311-pivotal-trial-of-cabozantinib-in-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer-prese\/"},"modified":"2024-07-23T10:09:53","modified_gmt":"2024-07-23T08:09:53","slug":"exelixis-and-ipsen-announce-detailed-results-from-phase-3-cosmic-311-pivotal-trial-of-cabozantinib-in-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer-prese","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/exelixis-and-ipsen-announce-detailed-results-from-phase-3-cosmic-311-pivotal-trial-of-cabozantinib-in-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer-prese\/","title":{"rendered":"Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021"},"content":{"rendered":"